[go: up one dir, main page]

CL2019000586A1 - Composiciones de toxinas clostridiales no proteicas. - Google Patents

Composiciones de toxinas clostridiales no proteicas.

Info

Publication number
CL2019000586A1
CL2019000586A1 CL2019000586A CL2019000586A CL2019000586A1 CL 2019000586 A1 CL2019000586 A1 CL 2019000586A1 CL 2019000586 A CL2019000586 A CL 2019000586A CL 2019000586 A CL2019000586 A CL 2019000586A CL 2019000586 A1 CL2019000586 A1 CL 2019000586A1
Authority
CL
Chile
Prior art keywords
compositions
clostridial toxins
antioxidant
surfactant
protein
Prior art date
Application number
CL2019000586A
Other languages
English (en)
Inventor
Maurice Abiad
Bhas Dani
Evgenyi Shalaev
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59974865&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2019000586(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CL2019000586A1 publication Critical patent/CL2019000586A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/84—Products or compounds obtained by lyophilisation, freeze-drying
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Birds (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)

Abstract

SE DESCRIBEN COMPOSICIONES FARMACÉUTICAS QUE ESTABILIZAN UN INGREDIENTE ACTIVO DE TOXINAS CLOSTRIDIALES. LAS COMPOSICIONES PUEDEN SER LÍQUIDAS O SÓLIDAS, Y COMPRENDEN UN SURFACTANTE Y UN ANTIOXIDANTE. EN ALGUNAS REALIZACIONES, LAS COMPOSICIONES COMPRENDEN UN SURFACTANTE SELECCIONADO A PARTIR DE UN POLOXÁMERO Y UN POLISORBATO; UN ANTIOXIDANTE SELECCIONADO A PARTIR DE METIONINA, N-ACETIL CISTEÍNA, ÁCIDO ETILENDIAMINATETRACÉTICO Y SUS COMBINACIONES; Y OPCIONALMENTE UN AGENTE DE TONICIDAD Y/O UN LIOPROTECTOR SELECCIONADO A PARTIR DE, POR EJEMPLO, TREHALOSA Y SACAROSA.
CL2019000586A 2016-09-13 2019-03-08 Composiciones de toxinas clostridiales no proteicas. CL2019000586A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662394009P 2016-09-13 2016-09-13

Publications (1)

Publication Number Publication Date
CL2019000586A1 true CL2019000586A1 (es) 2019-07-26

Family

ID=59974865

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000586A CL2019000586A1 (es) 2016-09-13 2019-03-08 Composiciones de toxinas clostridiales no proteicas.

Country Status (28)

Country Link
US (10) US20190247476A1 (es)
EP (4) EP3626259A1 (es)
JP (3) JP7217700B2 (es)
KR (6) KR102444230B1 (es)
CN (3) CN117959415A (es)
AU (4) AU2017326253B2 (es)
BR (2) BR112019004929A2 (es)
CA (2) CA3035473A1 (es)
CL (1) CL2019000586A1 (es)
CO (1) CO2019003630A2 (es)
CY (2) CY1122263T1 (es)
DK (2) DK3436054T4 (es)
ES (2) ES2755816T5 (es)
HR (1) HRP20191966T4 (es)
HU (2) HUE046290T2 (es)
IL (2) IL308091A (es)
LT (1) LT3436054T (es)
MX (2) MX2019002835A (es)
PH (1) PH12019500501A1 (es)
PL (2) PL3436054T5 (es)
PT (2) PT3436054T (es)
RS (1) RS59600B2 (es)
RU (2) RU2762607C2 (es)
SA (1) SA519401298B1 (es)
SI (2) SI3436054T2 (es)
SM (1) SMT201900625T1 (es)
TW (2) TW202247855A (es)
WO (2) WO2018053004A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
AU2017326253B2 (en) 2016-09-13 2021-10-21 Allergan, Inc. Stabilized non-protein clostridial toxin compositions
KR102649069B1 (ko) 2018-05-31 2024-03-19 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 안면 홍조 개선용 조성물
CN112261871B (zh) * 2018-07-28 2022-05-17 韩国外泌体生技有限公司 用于使外排体冻干的方法
KR102163806B1 (ko) 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
KR20210057129A (ko) * 2018-09-13 2021-05-20 알레간 인코포레이티드 클로스트리디움 독소-히알루론산 조성물
KR102259423B1 (ko) * 2018-11-30 2021-06-02 주식회사 휴온스바이오파마 보툴리눔 독소의 안정화 액상 조성물
WO2020231700A1 (en) * 2019-05-11 2020-11-19 Youngsuk Yi Neurotoxin compositions and methods
UY38744A (es) * 2019-06-07 2020-12-31 Nestle Skin Health S A Tratamiento de líneas glabelares y líneas cantales laterales de moderadas a muy graves
US11241479B2 (en) 2019-10-18 2022-02-08 Penland Foundation Treatment methods using botulinum toxins
US11090371B1 (en) 2019-10-18 2021-08-17 Penland Foundation Treatment of cirrhosis using botulinum toxin
US10973873B1 (en) 2019-10-18 2021-04-13 Penland Foundation Treatment of asthma using botulinum toxin
US10987411B1 (en) 2019-10-18 2021-04-27 Penland Foundation Treatment of chronic obstructive pulmonary disease using botulinum toxin
US10967052B1 (en) 2019-10-18 2021-04-06 Penland Foundation Treatment of dyslexia using botulinum toxin
AU2020365148B2 (en) 2019-10-18 2022-10-27 Penland Foundation Botulinum toxin for use in treatment
US11738071B2 (en) 2021-07-12 2023-08-29 Penland Foundation Treatment of acute and chronic kidney disease
US10960061B1 (en) 2019-10-18 2021-03-30 Penland Foundation Treatment of amyotrophic lateral sclerosis using botulinum toxin
WO2021231669A1 (en) * 2020-05-15 2021-11-18 Penland Foundation Treatment of cardiac arrhythmia using botulinum toxin
US10960060B1 (en) * 2019-10-18 2021-03-30 Penland Foundation Treatment of cardiac arrhythmia using botulinum toxin
RU2746035C1 (ru) * 2020-06-30 2021-04-06 Государственное бюджетное учреждение Санкт-Петербургский научно-исследовательский институт скорой помощи им. И.И. Джанелидзе Способ купирования болевого синдрома после эндопротезирования молочных желез
WO2023287728A1 (en) 2021-07-12 2023-01-19 Penland Foundation Treatment of diabetes and chronic pancreatitis using botulinum toxin
WO2024102345A1 (en) 2022-11-07 2024-05-16 Allergan, Inc. Prevention of post-operative atrial fibrillation with a botulinum toxin
GB202318884D0 (en) * 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation
CN118697853B (zh) * 2024-06-27 2025-05-02 河北封章生物科技有限公司 一种稳定性提高的肉毒素制剂

Family Cites Families (449)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0779694B2 (ja) 1985-07-09 1995-08-30 カドラント バイオリソ−シズ リミテツド 蛋白質および同類品の保護
US4958257A (en) 1989-03-29 1990-09-18 Hughes Aircraft Company Heat conducting interface for electronic module
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
IL101007A (en) 1992-02-18 1997-08-14 Pharmos Ltd Dry stable compositions prepared by lyophilization
EP0630257B1 (en) * 1992-03-13 2002-02-13 BEARDSLEY, Terry R. Thymus-derived, immune-enhancing agent for therapeutic use in immunocompromised hosts
JP3510886B2 (ja) 1992-06-23 2004-03-29 ボツリヌム トキシン リサーチ アソシエイト インコーポレイテッド ボツリヌスｂ複合体を含有する医薬組成物
DE69434443T2 (de) 1993-12-28 2006-05-24 Allergan, Inc., Irvine Verwendung der neutrotoxischen Komponente des Botulinum Toxins zur Muskelschmerzbehandlung
JP3066079B2 (ja) 1994-05-09 2000-07-17 ビンダー，ウィリアム，ジェイ． 頭痛を低減する方法
DK0760681T3 (da) 1994-05-31 2000-03-27 Allergan Inc Modifikation af clostridielle toksiner til anvendelse som transportproteiner
US5962637A (en) 1994-06-03 1999-10-05 Microbiological Research Authority Toxin assay
GB9411138D0 (en) 1994-06-03 1994-07-27 Microbiological Res Authority Toxin assay
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US5756468A (en) 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5556771A (en) 1995-02-10 1996-09-17 Gen-Probe Incorporated Stabilized compositions of reverse transcriptase and RNA polymerase for nucleic acid amplification
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
WO1996039166A1 (en) 1995-06-06 1996-12-12 Wisconsin Alumni Research Foundation Analogs of botulinum toxin and pharmaceutical compositions of botulinum toxin
AU6034396A (en) 1995-06-06 1996-12-24 L. Bruce Pearce Improved compositions and methods for chemodenervation using neurotoxins
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US8828432B2 (en) 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
TW518235B (en) 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
US6777196B2 (en) 1997-02-18 2004-08-17 Genentech, Inc. Neurturin receptor
DK1475099T4 (da) 1997-07-15 2014-05-19 Univ Colorado Anvendelse af botulinum-toksin til behandling af urininkontinens
US9066943B2 (en) 1997-07-15 2015-06-30 The Regents Of The University Of Colorado Use of botulinum toxin therapy for treatment of urological neurological conditions
US6638621B2 (en) 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
CN1073626C (zh) 1997-10-18 2001-10-24 卫生部兰州生物制品研究所 A型肉毒结晶毒素的生产工艺及生产该毒素所需的冻干保护液
SE510813C2 (sv) 1997-12-08 1999-06-28 Arla Ekonomisk Foerening Bakteriestam av arten Lactobacillus Paracasei subsp. paracasei, sammansättning därav för användning i livsmedel, samt produkt innehållande stammen
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US20050147690A1 (en) 1998-09-25 2005-07-07 Masters David B. Biocompatible protein particles, particle devices and methods thereof
ES2173678T3 (es) 1999-01-27 2002-10-16 Idea Ag Vacunacion no invasiva a traves de la piel.
PT1031347E (pt) 1999-01-27 2002-09-30 Idea Ag Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis
US6776990B2 (en) 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
US6573244B1 (en) 1999-05-17 2003-06-03 The United States Of America As Represented By The Secretary Of The Army Previns as specific inhibitors and therapeutic agents for Botulinum toxin B and Tetanus neurotoxins
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US6977080B1 (en) 1999-08-10 2005-12-20 Allergan, Inc. Intrapericardial botulinum toxin treatment for bradycardia
HK1046020B (en) 1999-08-25 2007-05-11 Allergan, Inc. Activatable recombinant neurotoxins
US20030180289A1 (en) 1999-09-23 2003-09-25 Foster Keith Alan Inhibition of secretion from non-neuronal cells
ATE454901T1 (de) 1999-10-13 2010-01-15 Novartis Vaccines & Diagnostic Verfahren zur erhaltung zellimmuneantworten gegen proteinen
IL149778A0 (en) 1999-11-22 2002-11-10 Universal Preservation Technologies Inc Preservation of sensitive biological material
US6500436B2 (en) 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
EP1398038B2 (en) 2000-02-08 2011-01-26 Allergan, Inc. Botulinum toxin pharmaceutical compositions
US20030138460A1 (en) 2000-02-08 2003-07-24 Allergan, Inc Methods of treating animals with botulinum toxin pharmaceutical compositions
US20060269575A1 (en) 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US8632785B2 (en) 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20040033241A1 (en) 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US7491799B2 (en) 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US6653062B1 (en) 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
US6630330B1 (en) 2000-08-02 2003-10-07 Biopolo S.C.A.R.L. Ascorbic acid production from yeast
HRP20030339A2 (en) 2000-10-31 2005-04-30 Boehringer Ingelheim Pharmaceuticals Inc. Oral dosage self-emulsifying formulations of pyranone protease inhibitors
US7223577B2 (en) 2000-11-17 2007-05-29 Allergan, Inc. Post-translational modifications and Clostridial neurotoxins
US7273722B2 (en) 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US7255865B2 (en) 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
ITUD20010002A1 (it) 2001-01-05 2002-07-05 Univ Degli Studi Udine Uso della tossina botulinica per la soluzione di patologie articolari, in particolare della coxartrosi, della epicondilite e della patolo
US20060134140A1 (en) 2001-04-12 2006-06-22 Dana Lasko Compositions and methods for treating tumor spreading
US7442686B2 (en) 2001-04-12 2008-10-28 Bioaxone Therapeutique Inc. Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions
AU2002338436A1 (en) 2001-04-25 2002-11-05 Hernan F. Acevedo Hcg formulation
US9157875B2 (en) 2001-05-16 2015-10-13 Benjamin P. Warner Drug development and manufacturing
US8022172B2 (en) 2001-08-28 2011-09-20 Allergan, Inc. Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
US7208285B2 (en) 2001-08-28 2007-04-24 Allergan, Inc. Fret protease assays for botulinum serotype A/E toxins
US7332567B2 (en) 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US20030104996A1 (en) 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
MXPA01011542A (es) 2001-11-13 2003-05-22 Alcon Inc Regeneracion del cartilago articular da°ado por la osteoartritis de grado i y ii, mediante la aplicacion intra-articular de una mezcla de hialuronato de sodio y de condroitin sulfato en un vehiculo de gel.
US7691394B2 (en) 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US7183066B2 (en) 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
AU2003287105A1 (en) 2002-10-10 2004-05-04 Verenium Corporation Proteases, nucleic acids encoding them and methods for making and using them
NZ540166A (en) 2002-10-25 2007-06-29 Foamix Ltd Cosmetic and pharmaceutical foam
US20040086532A1 (en) 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
WO2004043534A1 (en) 2002-11-12 2004-05-27 Collegium Pharmaceutical, Inc. Inertial drug delivery system
US20060074014A1 (en) 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20060002862A1 (en) 2002-12-17 2006-01-05 Medimmune Vaccines, Inc. High pressure spray-dry of bioactive materials
ZA200504982B (en) 2002-12-20 2007-05-30 Botulinum Toxin Res Ass Inc Pharmaceutical botulinum toxin compositions
GB0300427D0 (en) 2003-01-09 2003-02-05 Univ Strathclyde Pharmaceutical composition
ATE512136T1 (de) 2003-01-16 2011-06-15 Acadia Pharm Inc Selektive serotonin-2a/2c-rezeptor- inversagonisten als therapeutika für neurogenerative erkrankungen
US7758872B1 (en) 2003-02-07 2010-07-20 Eric Finzi Method of treating depression
EP1599213A4 (en) 2003-02-24 2009-07-15 Ira Sanders CELL MEMBRANE TRANSLOCATION OF SNARE R GUL S INHIBITORS, ASSOCIATED COMPOSITIONS AND PATHOLOGY TREATMENT PROCESSES
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EP2405015B1 (en) 2003-03-05 2016-01-06 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20040214753A1 (en) 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
US20040204471A1 (en) 2003-03-20 2004-10-14 Pharmacia Corporation Treatment and prevention of otic disorders with Cox-2 inhibitors alone or in combination with otic agents
JP5503837B2 (ja) 2003-03-26 2014-05-28 ポール，サッドヒル 非共有結合により誘導される求核性タンパク質へのリガンドの共有結合
WO2005030119A2 (en) 2003-04-11 2005-04-07 Allergan, Inc. Botulinum toxin a peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
US7396535B2 (en) 2003-04-25 2008-07-08 Ackerman Alan H Therapy for obsessive compulsive head banging
US7393537B2 (en) 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
CN1845708A (zh) 2003-07-02 2006-10-11 阿尔扎公司 微突出物阵列免疫贴剂和方法
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US20050042775A1 (en) 2003-08-21 2005-02-24 Nicholas Pomato Botulinum antitoxin compositions and methods
WO2005034852A2 (en) 2003-08-26 2005-04-21 Gel-Del Technologies, Inc. Protein biomaterials and biocoacervates and methods of making and using thereof
US7160699B2 (en) 2003-09-25 2007-01-09 Allergan, Inc. Media for clostridium bacterium and processes for obtaining a clostridial toxin
US7148041B2 (en) 2003-09-25 2006-12-12 Allergan, Inc. Animal product free media and processes for obtaining a botulinum toxin
US8609112B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
JP2007509704A (ja) 2003-10-31 2007-04-19 アルザ・コーポレーシヨン 経皮的ワクチン送達のための系および方法
KR20070011252A (ko) 2003-11-21 2007-01-24 알자 코포레이션 초음파 보조 경피 백신전달방법 및 시스템
GB0328060D0 (en) 2003-12-04 2004-01-07 Sod Conseils Rech Applic Botulinum toxin treatment
AU2004296851A1 (en) 2003-12-08 2005-06-23 Gel-Del Technologies, Inc. Mucoadhesive drug delivery devices and methods of making and using thereof
WO2005063714A1 (en) 2003-12-23 2005-07-14 Infinity Pharmaceuticals, Inc Analogs of benzoquinone-containing ansamycins for the treatment of cancer
JP2007519446A (ja) 2004-01-09 2007-07-19 アルザ・コーポレーシヨン 振動支援型の経皮的な薬剤の送達法および系
FR2865131B1 (fr) 2004-01-15 2007-08-24 Gattefosse Ets Sa Utilisation d'un extrait d'acmella oleracea pour son effet botox like dans une composition cosmetique anti-rides
JP4970057B2 (ja) 2004-02-24 2012-07-04 アラーガン、インコーポレイテッド ボツリヌス毒素スクリーニングアッセイ
US20050191321A1 (en) 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US9078892B2 (en) 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
KR101322433B1 (ko) 2004-03-03 2013-10-28 레반스 테라퓨틱스, 아이엔씨. 보툴리눔 독소의 국소 적용 및 경피 전달을 위한 조성물 및 방법
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US7674454B2 (en) 2004-03-06 2010-03-09 Innovata Limited Enzyme-prodrug therapy for prosthetic joint repair
US20050214325A1 (en) 2004-03-26 2005-09-29 Vvii Newco 2003, Inc. Compositions and methods to increase the effect of a neurotoxin treatment
KR20060135931A (ko) 2004-04-01 2006-12-29 알자 코포레이션 인플루엔자 백신의 경피전달 장치 및 방법
WO2005098009A2 (en) 2004-04-09 2005-10-20 Wyeth Synergistic attenutation of vesicular stomatitis virus, vectors thereof and immunogenic compositions thereof
CA2562642A1 (en) 2004-04-13 2005-11-03 Alza Corporation Apparatus and method for transdermal delivery of multiple vaccines
ES2297742T3 (es) 2004-05-05 2008-05-01 Pharmaleads Sustratos peptidicos reconocidos por la toxina botulinica de tipo a, bont/a y sus usos.
US7591806B2 (en) 2004-05-18 2009-09-22 Bai Xu High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances
CN101433091A (zh) 2004-05-19 2009-05-13 阿尔扎公司 用于透皮传递免疫活性剂的方法和制剂
DE102004026152A1 (de) 2004-05-28 2005-12-15 Basf Ag Fermentative Herstellung von Feinchemikalien
JP2008502605A (ja) 2004-06-16 2008-01-31 スマート ドラッグ システムズ インコーポレイティド 徐放性ワクチン組成物
BRPI0512660A (pt) 2004-06-28 2008-04-01 Lifecycle Pharma As tablete carregável, e, método para a preparação de um tablete
US7514088B2 (en) 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
WO2006011966A1 (en) 2004-06-30 2006-02-02 Allergan, Inc. Optimizing expression of active botulinum toxin type e
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
MX2007000794A (es) 2004-07-26 2007-04-09 Merz Pharma Gmbh & Co Kgaa Composicion terapeutica con una neurotoxina botulinica.
GB2419527A (en) 2004-10-28 2006-05-03 Ipsen Ltd Pharmaceutical composition containing botulinum neurotoxin
EP1776137B1 (en) 2004-08-04 2014-11-26 Ipsen Biopharm Limited Pharmaceutical composition containing botulinum neurotoxin a2
CA2575994A1 (en) 2004-08-04 2006-02-16 Allergan, Inc. Optimizing expression of active botulinum toxin type a
US7892565B2 (en) 2004-09-01 2011-02-22 Allergan, Inc. Degradable clostridial toxins
PL1797109T3 (pl) 2004-09-09 2016-11-30 Mieszaniny polipeptydów, kompozycje zawierające je i procesy ich wytwarzania oraz ich zastosowania
US20060057165A1 (en) 2004-09-10 2006-03-16 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
US7399607B2 (en) 2004-09-22 2008-07-15 Allergan, Inc. Fluorescence polarization assays for determining clostridial toxin activity
CA2582096C (en) 2004-10-01 2014-01-07 Ramscor, Inc. Conveniently implantable sustained release drug compositions
WO2006042149A2 (en) 2004-10-06 2006-04-20 Allergan, Inc. Determining and reducing immunoresistance to botulinum toxin therapy using botulinum toxin a peptides
US7205018B2 (en) 2004-10-07 2007-04-17 Next Proteins, Inc. Carbonated protein drink and method of making
ES2394455T3 (es) 2004-11-02 2013-01-31 Chr. Hansen A/S Formulaciones de bacteriófagos estabilizados
WO2007001451A2 (en) 2004-11-09 2007-01-04 Board Of Regents, The University Of Texas System Stabilized hme composition with small drug particles
WO2006059105A2 (en) 2004-12-01 2006-06-08 Health Protection Agency Non-cytotoxic Protein Conjugates
AU2005311086B2 (en) 2004-12-01 2012-03-29 Allergan, Inc. Fusion proteins
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US8192979B2 (en) 2005-01-03 2012-06-05 Botulinum Toxin Research Associates, Inc. Compositions, methods and devices for preparing less painful Botulinum toxin formulations
US7727537B2 (en) 2005-02-14 2010-06-01 Dpm Therapeutics Corp. Stabilized compositions for topical administration and methods of making same
US7838011B2 (en) 2005-02-14 2010-11-23 Pankaj Modi Stabilized protein compositions for topical administration and methods of making same
US20080220021A1 (en) 2005-02-14 2008-09-11 Pankaj Modi Topical Botulinum Toxin Compositions for the Treatment of Hyperhidrosis
BRPI0608249A2 (pt) 2005-03-03 2009-12-08 Revance Therapeutics Inc formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica
CN1946738A (zh) 2005-03-03 2007-04-11 阿勒根公司 用于纯化肉毒毒素的不含动物产物的系统和方法
AU2006225116B2 (en) 2005-03-15 2012-04-19 Allergan, Inc. Modified Clostridial toxins with altered targeting capabilities for Clostridial toxin target cells
JP5190654B2 (ja) 2005-03-31 2013-04-24 国立大学法人広島大学 分子マーカーを用いた間葉系幹細胞の識別方法及びその利用
CA2604039C (en) 2005-04-05 2014-09-16 Allergan, Inc. Lipophilic dye-based fret assays for clostridial toxin activity
US20070029252A1 (en) 2005-04-12 2007-02-08 Dunson James B Jr System and process for biomass treatment
WO2006122123A2 (en) 2005-05-09 2006-11-16 Levin Bruce H Methods of alleviating disorders and their associated pain
US8926991B2 (en) 2005-06-14 2015-01-06 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
US9789179B2 (en) 2005-06-27 2017-10-17 Glaxosmithkline Biologicals S.A. Immunogenic composition
US8323666B2 (en) 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US20070036831A1 (en) 2005-08-09 2007-02-15 Nanobio Corporation Nanoemulsion compositions having anti-inflammatory activity
WO2007035455A2 (en) 2005-09-16 2007-03-29 Merial Limited Stabilizers for freeze-dried vaccines
ES2341892T5 (es) 2005-09-19 2019-03-27 Allergan Inc Toxina clostridial activable por toxinas clostridiales
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
AU2013202329B2 (en) * 2005-10-06 2016-04-14 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
CN101175478A (zh) * 2005-10-06 2008-05-07 阿勒根公司 非蛋白稳定的梭菌毒素药物组合物
US20090324647A1 (en) 2005-10-11 2009-12-31 Borodic Gary E Albumin-Free Botulinum Toxin Based Pharmaceutical Compositions Containing a Hyaluronidase and Methods of Use
DE102005051789B4 (de) 2005-10-28 2014-08-07 Toxogen Gmbh Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
CN101326292A (zh) 2005-12-08 2008-12-17 诺瓦提斯公司 Fgfr3抑制物对基因转录的影响
DK3326681T3 (da) 2005-12-30 2019-09-30 Rdd Pharma Ltd Indretning til behandling af analsphincteren
AU2007204755A1 (en) 2006-01-10 2007-07-19 Eugene J. Van Scott N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use
KR101501780B1 (ko) 2006-01-24 2015-03-16 넥스바이오, 인코퍼레이티드 고분자 미소 구체들의 조제를 위한 기술
WO2007111806A2 (en) 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
EP2105500A1 (de) 2008-03-26 2009-09-30 Pharmazell GmbH Neue 12alpha-Hydroxysteroiddehydrogenasen, deren Herstellung und deren Verwendung
US7473559B2 (en) 2006-04-05 2009-01-06 Charles Lee Method for measuring the content of a botulinum toxin in a formulation
US7309602B2 (en) 2006-04-13 2007-12-18 Ambrozea, Inc. Compositions and methods for producing fermentation products and residuals
ITTO20060282A1 (it) 2006-04-14 2007-10-15 Univ Degli Studi Torino Mezzo di coltura e composizione farmaceutica per la rigenerazione del tessuto cartilagineo relativo procedimento relativi usi e prodotti
JP2009543557A (ja) 2006-07-11 2009-12-10 アラーガン、インコーポレイテッド 増強した転位置能力およびクロストリジウム毒素標的細胞に対する変化したターゲティング活性を有する改変クロストリジウム毒素
JP2009543556A (ja) 2006-07-11 2009-12-10 アラーガン、インコーポレイテッド 増強した転位置能力および増強したターゲティング活性を有する改変クロストリジウム毒素
DE102006035618A1 (de) 2006-07-31 2008-02-07 Curevac Gmbh Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
WO2008021210A2 (en) 2006-08-11 2008-02-21 Combinatorx, Incorporated Methods and compositions for the treatment of neurodegenerative disorders
US9061025B2 (en) 2006-08-31 2015-06-23 Allergan, Inc. Methods for selecting headache patients responsive to botulinum toxin therapy
US8043845B2 (en) 2006-09-20 2011-10-25 American Sterilizer Company Sterilization indicator
JP5143841B2 (ja) 2006-10-10 2013-02-13 ロス アラモス ナショナル セキュリティー，エルエルシー 高度な薬物開発及び製造
EP1917971A1 (en) 2006-10-27 2008-05-07 Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) Substained release formulations comprising very low molecular weight polymers
EP1921149A1 (en) 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
CN101848702B (zh) 2006-12-01 2013-07-17 安特里奥公司 两亲实体纳米粒子
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
EP2131857B1 (en) 2007-03-22 2015-07-29 The Regents of the University of Colorado, a body corporate Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
WO2008133884A2 (en) 2007-04-23 2008-11-06 Combinatorx, Incorporated Methods and compositions for the treatment of neurodegenerative disorders
EP1985276A1 (en) 2007-04-26 2008-10-29 Merz Pharma GmbH & Co. KGaA Treatment of movement disorders by a combined use of a chemodenervating agent and automated movement therapy
CN101687046B (zh) 2007-07-10 2012-12-26 株式会社美地拓斯 稳定性改善的肉毒毒素药物液体组合物
MX2010002815A (es) 2007-09-14 2010-07-30 Sanofi Pasteur Biologics Co Composiciones farmaceuticas que contienen toxoides a y b de clostridium difficile.
US8486467B1 (en) 2007-09-20 2013-07-16 Albert G. Prescott Dermal filler and method of using same
MX2010003642A (es) 2007-10-12 2010-08-09 Massachusetts Inst Technology Nanotecnologia de vacuna.
TWI629064B (zh) 2007-11-30 2018-07-11 艾伯維生物技術有限責任公司 蛋白質調配物及製造其之方法
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
JP2011505149A (ja) 2007-11-30 2011-02-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ハロゲン化メチルトランスフェラーゼを発現する組換え型生物を用いた、有機化合物の工業的生産方法
US9044477B2 (en) 2007-12-12 2015-06-02 Allergan, Inc. Botulinum toxin formulation
US9161970B2 (en) 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
KR20110007088A (ko) 2008-01-25 2011-01-21 비 앤드 티 에스.알.엘. 화장품 분야에서의 트랜스에스테르화 올리브 오일의 용도
US9226959B2 (en) 2008-01-31 2016-01-05 Curevac Ag Nucleic acids comprising formula (NuGlXmGnNv)a and derivatives thereof as immunostimulating agent/adjuvant
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
AU2009223161B2 (en) 2008-03-14 2014-10-30 Allergan, Inc. Immuno-based botulinum toxin serotype A activity assays
KR101604515B1 (ko) 2008-03-14 2016-03-17 알러간, 인코포레이티드 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정
US9233080B2 (en) 2008-03-27 2016-01-12 Agigma, Inc. Compositions and methods for the delivery of agents
US8617571B2 (en) 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
US9119866B2 (en) 2008-04-08 2015-09-01 Huiru Wang Glycan-based drugs, therapies and biomarkers
WO2009128644A2 (ko) 2008-04-14 2009-10-22 한국과학기술원 게놈 수준에서의 부탄올 생산 미생물의 대사 네트워크 모델 및 이를 이용한 부탄올 생성 미생물의 대사특성분석 및 결실 표적 스크리닝 방법
MX2010011975A (es) 2008-04-30 2011-01-21 Xyleco Inc Procesamiento de biomasa.
KR20090120222A (ko) 2008-05-19 2009-11-24 (주)메디톡스 식물 유래 성분 함유 배지 및 가요성 폐쇄 용기를 이용하여클로스트리디움 보툴리눔 독소를 생산하는 방법
AU2009248810B2 (en) 2008-05-23 2013-12-05 The Regents Of The University Of Michigan Nanoemulsion vaccines
BRPI0914630A2 (pt) 2008-06-26 2019-09-24 Anterios Inc liberação dérmica
WO2010011597A2 (en) 2008-07-22 2010-01-28 Mayo Foundation For Medical Education And Research Treatment of obesity and related disorders
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
ES2560281T3 (es) 2008-10-17 2016-02-18 Joule Unlimited Technologies, Inc. Producción de etanol por microorganismos
US9072688B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
AU2009313201B2 (en) 2008-11-10 2016-06-16 Arbutus Biopharma Corporation Novel lipids and compositions for the delivery of therapeutics
EP2364168A1 (en) 2008-12-04 2011-09-14 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
WO2010090677A1 (en) * 2008-12-10 2010-08-12 Allergan, Inc. Clostridial toxin pharmaceutical compositions
CN102281870B (zh) 2008-12-10 2015-03-04 安徽中人科技有限责任公司 新型控释组合物
EP2358760B1 (en) 2008-12-19 2015-02-18 Momenta Pharmaceuticals, Inc. Characterization of o-linked glycans
US20100168023A1 (en) 2008-12-31 2010-07-01 Revance Therapeutics, Inc. Injectable Botulinum Toxin Formulations
SG2014007389A (en) 2009-01-29 2014-04-28 Forsight Vision4 Inc Posterior segment drug delivery
US9744237B2 (en) 2009-01-29 2017-08-29 Kambiz Thomas Moazed Method and system for effecting changes in pigmented tissue
CA2751311C (en) 2009-02-19 2019-08-06 Merz Pharma Gmbh & Co. Kgaa Means and methods for manufacturing highly pure neurotoxin
DK2406371T3 (en) 2009-03-13 2018-08-13 Allergan Inc USEFUL CELLS FOR IMMUNE BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY TEST
PT3281953T (pt) 2009-03-13 2020-01-15 Allergan Inc Ensaios de base imunológica da actividade de endopeptidase redireccionada
CA2757449A1 (en) 2009-04-01 2010-10-07 Revance Therapeutics, Inc. Methods and compositions for treating skin conditions associated with vascular hyper-reactivity
EP2248518B1 (en) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
US20180027833A1 (en) 2009-04-24 2018-02-01 Nestec S.A. Shelf-stable fermented dairy products and methods of making same
ES2613604T3 (es) 2009-04-24 2017-05-24 Nestec S.A. Fermentos lácteos fermentados, estables a la conservación, y procedimientos para la elaboración de los mismos
US9539233B2 (en) 2009-05-04 2017-01-10 Aridis Pharmaceuticals Inc. Gallium formulation for the treatment and prevention of infectious diseases
NZ621981A (en) 2009-05-05 2015-09-25 Tekmira Pharmaceuticals Corp Lipid compositions
US9545360B2 (en) 2009-05-13 2017-01-17 Sio2 Medical Products, Inc. Saccharide protective coating for pharmaceutical package
HRP20211619T1 (hr) 2009-06-10 2022-02-04 Arbutus Biopharma Corporation Poboljšana formulacija lipida
EP2445481B1 (en) 2009-06-18 2017-03-22 Rdd Pharma Ltd. Methods and devices for delivery of pharmaceutical agents within orifices of the body
KR101595033B1 (ko) 2009-06-24 2016-02-17 챨스 엔.에스. 소파카 메탈로프로테아제 치료에 대한 반응성을 증대시키기 위한 아연 보충 방법
US20120107431A1 (en) 2009-06-30 2012-05-03 Dong Hyun Kim Cosmetic composition containing a rubus coreanus extract for diminishing skin wrinkles
AU2010265888A1 (en) * 2009-06-25 2012-01-19 Revance Therapeutics, Inc. Albumin-free botulinum toxin formulations
US9458536B2 (en) 2009-07-02 2016-10-04 Sio2 Medical Products, Inc. PECVD coating methods for capped syringes, cartridges and other articles
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
IN2012DN00345A (es) 2009-07-24 2015-05-08 Univ California
EP2464341B1 (en) 2009-08-12 2022-07-06 Sublimity Therapeutics Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
US20110059079A1 (en) 2009-09-04 2011-03-10 Xoma Technology Ltd. Antibody Coformulations
WO2011028961A2 (en) 2009-09-04 2011-03-10 Xoma Technology Ltd. Anti-botulism antibody coformulations
CN102597252A (zh) 2009-09-14 2012-07-18 Gs加特克斯公司 生物燃料物质及生物化学物质的制备方法
CN102666863A (zh) 2009-12-15 2012-09-12 思德力公司 从稀的水溶液中回收有机组分的方法
CN102933200B (zh) 2009-12-18 2015-11-25 莱迪杜德制药公司 包含磷脂的单相凝胶组合物
EP2525777B1 (en) 2010-01-20 2019-05-29 UroGen Pharma Ltd. Material and method for treating internal cavities
US10471150B2 (en) 2010-01-20 2019-11-12 Urogen Pharma Ltd. Material and method for treating internal cavities
WO2011103465A2 (en) 2010-02-20 2011-08-25 Alexey Gennadievich Zdanovsky Botulinum neurotoxin antigenic compositions and methods
GB201004072D0 (en) 2010-03-11 2010-04-28 Turzi Antoine Process, tube and device for the preparation of wound healant composition
US9327105B2 (en) 2010-03-26 2016-05-03 Itrace Biomedical Inc. Active transdermal drug delivery system and the method thereof
US8940308B2 (en) 2010-03-30 2015-01-27 Allergan, Inc. Methods for treating depression
JP6324068B2 (ja) 2010-05-26 2018-05-23 セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 合成ナノキャリア混合ワクチン
BRPI1002601E2 (pt) 2010-06-01 2020-06-30 Embrapa Pesquisa Agropecuaria composição nanoestruturada de uso veterinário para administração de fármacos
KR101209266B1 (ko) 2010-06-30 2012-12-06 한국과학기술연구원 생분해성 및 온도 감응성 폴리포스파젠계 자성 고분자, 그의 제조 방법 및 용도
WO2012015912A1 (en) 2010-07-30 2012-02-02 Medimmune, Llc Method for purifying active polypeptides or immunocojugates
WO2012048854A2 (en) 2010-10-12 2012-04-19 Merz Pharma Gmbh & Co. Kgaa Formulation suitable for stabilizing proteins, which is free of mammalian excipients
US8685381B2 (en) 2010-10-23 2014-04-01 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
CA2815259A1 (en) 2010-10-27 2012-05-03 Quantibact A/S Capture of target dna and rna by probes comprising intercalator molecules
JP2013544516A (ja) 2010-11-03 2013-12-19 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア タンパク質性バイオマスの発酵を介した組換え微生物によるバイオ燃料および化学物質の生成
FR2967913A1 (fr) 2010-11-29 2012-06-01 Vetalis Composition galenique adaptee a l'administration a un animal non-humain, utilisations de celle-ci et methodes associees
RS56460B1 (sr) 2011-01-07 2018-01-31 Revance Therapeutics Inc Topikalna supstanca koja sadrži botulinski toksin i boju
US20120328701A1 (en) 2011-01-24 2012-12-27 Anterios, Inc. Nanoparticle compositions, formulations thereof, and uses therefor
ES2720659T3 (es) 2011-02-15 2019-07-23 Vaxiion Therapeutics Llc Composiciones terapéuticas y métodos para la administración dirigida, mediante minicélulas bacterianas, de moléculas bioactivas basadas en moléculas dirigidas que contienen Fc y anticuerpos
CA2827956C (en) 2011-02-23 2019-05-07 Ams Research Corporation Drug releasing pelvic treatment system and method
US20120222979A1 (en) 2011-03-04 2012-09-06 Elwha LLC, a limited liability company of the State of Delaware Glassy compositions
JP6063877B2 (ja) * 2011-03-10 2017-01-18 ゼリス ファーマシューティカルズ インコーポレイテッド ペプチド薬物の非経口注射用の安定な製剤
BR112013025047A2 (pt) 2011-03-31 2017-02-14 Nestec Sa composições nutricionais para aumentar os níveis de arginina e métodos para usar as mesmas
SG194039A1 (en) 2011-03-31 2013-11-29 Medy Tox Inc Lyophilized preparation of botulinum toxin
WO2012137201A1 (en) 2011-04-07 2012-10-11 Hcl Cleantech Ltd. Lignocellulose conversion processes and products
JP2014511871A (ja) 2011-04-12 2014-05-19 ネステク ソシエテ アノニム 分枝鎖脂肪酸を含む栄養組成物及びその使用方法
AU2012244751A1 (en) 2011-04-18 2013-10-17 Nestec S.A. Nutritional compositions having alpha-HICA and alpha-ketoglutarate
DK2707031T3 (da) 2011-05-08 2019-10-07 Legochem Biosciences Inc Protein-active agent conjugates and method for preparing the same
US20130309273A1 (en) 2012-05-17 2013-11-21 Kimberly Hassett Thermostable Vaccine Compositions and Methods of Preparing Same
CA2836273C (en) 2011-05-17 2019-01-15 Soligenix, Inc. Thermostable vaccine compositions and methods of preparing same
CA2839511C (en) 2011-06-17 2018-07-31 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
US8586020B2 (en) 2011-06-30 2013-11-19 Korea Institute Of Science And Technology Poly(organophosphazene) composition for biomaterials
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
US20130053792A1 (en) 2011-08-24 2013-02-28 Ablative Solutions, Inc. Expandable catheter system for vessel wall injection and muscle and nerve fiber ablation
KR20130022923A (ko) 2011-08-26 2013-03-07 삼성전자주식회사 가상 시점 합성 예측을 이용한 부호화/복호화 장치 및 부호화/복호화 방법
EP2771295B1 (en) 2011-10-25 2017-11-22 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CN113149869A (zh) 2011-10-27 2021-07-23 麻省理工学院 能够形成药物包封微球的在n末端上官能化的氨基酸衍生物
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
CN103930595A (zh) 2011-11-11 2014-07-16 Sio2医药产品公司 用于药物包装的钝化、pH保护性或润滑性涂层、涂布方法以及设备
US9554968B2 (en) 2013-03-11 2017-01-31 Sio2 Medical Products, Inc. Trilayer coated pharmaceutical packaging
EP2790531B1 (en) 2011-12-15 2022-01-19 Société des Produits Nestlé S.A. Cohesive thin liquids to promote safe swallowing in dysphagic patients
BR112014014329A2 (pt) 2011-12-15 2017-06-13 Nestec Sa viscosidade extensional para promover deglutição segura de bolos alimentares
EA030252B9 (ru) 2011-12-30 2021-09-08 Галозим, Инк. Варианты полипептидов ph20, композиции на их основе и их применение
EP2634190A1 (en) 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
KR102024109B1 (ko) 2012-04-26 2019-09-23 아디쎄오 프랑스 에스에이에스 2,4-다이하이드록시부티르산의 제조 방법
EP2866854B1 (en) 2012-06-29 2020-08-05 Cytosorbents Corporation Polymers for use in methods
JP6488232B2 (ja) 2012-07-03 2019-03-20 エスアイオーツー・メディカル・プロダクツ・インコーポレイテッド 薬剤パッケージのＳｉＯｘバリア及び被覆プロセス
US20150297800A1 (en) 2012-07-03 2015-10-22 Sio2 Medical Products, Inc. SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS
EP2869845B1 (en) 2012-07-06 2019-08-28 Genmab B.V. Dimeric protein with triple mutations
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
US9561194B2 (en) 2012-07-31 2017-02-07 Nestec S.A. Nutritional composition for promoting musculoskeletal health in patients with inflammatory bowel disease (IBD)
ES2954516T3 (es) 2012-08-05 2023-11-22 Absci Corp Sistema de coexpresión inducible
US10980865B2 (en) 2012-08-10 2021-04-20 Aquavit Pharmaceuticals, Inc. Direct application system and method for the delivery of bioactive compositions and formulations
WO2015020982A2 (en) 2013-08-04 2015-02-12 Aquavit Pharmaceuticals, Inc. Direct application system and method for the delivery of bioactive compositions and formulations
US10894062B2 (en) 2012-08-10 2021-01-19 Aquavit Pharmaceuticals, Inc. Vitamin supplement compositions for injection
FR2996855B1 (fr) 2012-10-16 2016-11-11 Lesaffre & Cie Souches de levures pour la production de biomasse sur un substrat comprenant un sucre en c5, leurs procedes d'obtention et utilisations de la biomasse produite
US20140120077A1 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and Methods for Safe Treatment of Rhinitis
GB201219602D0 (en) 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
US10087432B2 (en) 2012-11-21 2018-10-02 Ipsen Bioinnovation Limited Methods for the manufacture of proteolytically processed polypeptides
WO2014078911A1 (en) 2012-11-26 2014-05-30 Borody Thomas J Compositions for the restoration of a fecal microbiota and methods for making and using them
JP6431484B2 (ja) 2012-12-28 2018-11-28 セルスティス リミテッド 細胞媒介免疫応答アッセイ
CN105050422A (zh) 2013-01-11 2015-11-11 非凡食品有限公司 包含凝聚物的非乳制干酪仿品
WO2014124096A1 (en) 2013-02-06 2014-08-14 Perosphere Inc. Stable glucagon formulations
US9650608B2 (en) 2013-02-22 2017-05-16 Medivet America, Llc Activating adipose-derived stem cells for transplantation
WO2014134577A1 (en) 2013-03-01 2014-09-04 Sio2 Medical Products, Inc. Plasma or cvd pre-treatment for lubricated pharmaceutical package, coating process and apparatus
US9937099B2 (en) 2013-03-11 2018-04-10 Sio2 Medical Products, Inc. Trilayer coated pharmaceutical packaging with low oxygen transmission rate
CA2909620A1 (en) 2013-03-13 2014-10-02 President And Fellows Of Harvard College Stapled and stitched polypeptides and uses thereof
EP2986140A4 (en) 2013-03-15 2016-10-19 Nusirt Sciences Inc COMPOSITIONS, PROCESSES AND KIT FOR TREATMENT OF PETS
EP2970389B1 (en) 2013-03-15 2020-08-19 Rhythm Pharmaceuticals, Inc. Pharmaceutical compositions
US9603799B2 (en) 2013-03-15 2017-03-28 Htd Biosystems Inc. Liposomal vaccine adjuvants and methods of making and using same
EP2968206A4 (en) 2013-03-15 2016-09-21 Nusirt Sciences Inc TREATMENT OF PETS WITH SIRTUIN ACTIVATORS
JP2016516419A (ja) 2013-03-26 2016-06-09 プレミア・ニュートリション・コーポレイション 同時トレーニングに続いて筋タンパク質合成を高めるための方法
US20160151482A1 (en) 2013-04-02 2016-06-02 Stc. Unm Mesoporous alum nanoparticles as a universal platform for antigen adsorption, presentation, and delivery
CN105377045A (zh) 2013-04-16 2016-03-02 雀巢产品技术援助有限公司 架藏稳定的发酵乳制品及其制造方法
RU2535115C1 (ru) 2013-05-15 2014-12-10 Бости Трейдинг Лтд Фармацевтический состав, содержащий нейротоксин ботулина
WO2014186754A2 (en) 2013-05-16 2014-11-20 Board Of Regents The University Of Texas System Dry solid aluminum adjuvant-containing vaccines and related methods thereof
CN103257233B (zh) 2013-05-31 2015-08-05 南京祥中生物科技有限公司 一种同时可视化检测多种抗生素、非法添加剂及生物毒素的生物芯片及方法
WO2015000972A1 (en) 2013-07-02 2015-01-08 Sg Austria Pte Ltd A method of freeze-drying encapsulated cells, freeze-dried encapsulated cells, compositions containing freeze-dried encapsulated cells and uses of such cells and compositions
WO2015023989A1 (en) 2013-08-15 2015-02-19 Lallemand Hungary Liquidity Management Llc Methods for the improvement of product yield and production in a microorganism through glycerol recycling
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
CN103705913A (zh) * 2013-12-27 2014-04-09 柳州市工人医院 A型肉毒毒素在制备治疗雷诺综合征药物的应用
CN106062176A (zh) 2014-01-02 2016-10-26 特雷里斯公司 用于在氢营养微生物中生物制备氨基酸的组合物和方法
US10260111B1 (en) 2014-01-20 2019-04-16 Brett Eric Etchebarne Method of detecting sepsis-related microorganisms and detecting antibiotic-resistant sepsis-related microorganisms in a fluid sample
US10071103B2 (en) 2014-01-29 2018-09-11 Vyome Biosciennces Pvt. Ltd. Treatments for resistant acne
US20170007675A1 (en) 2014-02-06 2017-01-12 Xeris Pharmaceuticals, Inc. Stable peptide formulations and methods for preparation
CA2938790A1 (fr) 2014-02-14 2015-08-20 Vesale Pharma Sa Composition comprenant du bifidobacterium animalis ssp. lactis
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
US9389162B2 (en) 2014-04-10 2016-07-12 City University Of Hong Kong Detection of analyte using coffee-ring effect
WO2015157595A1 (en) 2014-04-11 2015-10-15 Medimmune, Llc Conjugated compounds comprising cysteine-engineered antibodies
US10689674B2 (en) 2014-04-15 2020-06-23 Industrial Microbes, Inc. Synthetic methanotrophic and methylotrophic microorganism and method thereof
GB201407525D0 (en) 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
DK3137053T3 (da) * 2014-04-30 2020-09-07 Allergan Inc Formuleringer af biologiske lægemidler til intravesikal instillation
WO2015184327A1 (en) 2014-05-30 2015-12-03 Braskem S.A. Modified microorganisms comprising an optimized system for oligosaccharide utilization and methods of using same
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
SG11201700552SA (en) 2014-07-23 2017-02-27 Landy Toth Precision chemical ablation and treatment of tissues
CN107105749A (zh) 2014-08-13 2017-08-29 阿克索生物医药公司 抗微生物化合物和组合物及其用途
WO2016029146A1 (en) 2014-08-22 2016-02-25 University Of Washington Specific inhibitors of methionyl-trna synthetase
US10729896B2 (en) 2014-09-23 2020-08-04 Avidas Pharmaceuticals Llc Delivery and induction of therapeutic agents and uses thereof
US10366793B2 (en) 2014-10-21 2019-07-30 uBiome, Inc. Method and system for characterizing microorganism-related conditions
US10325685B2 (en) 2014-10-21 2019-06-18 uBiome, Inc. Method and system for characterizing diet-related conditions
US10410749B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
US10357157B2 (en) 2014-10-21 2019-07-23 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features
US10381112B2 (en) 2014-10-21 2019-08-13 uBiome, Inc. Method and system for characterizing allergy-related conditions associated with microorganisms
US9710606B2 (en) 2014-10-21 2017-07-18 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
BR102014028009B1 (pt) 2014-11-10 2023-04-18 Universidade Federal De Pelotas Composições filmogênicas para bioadesivos anestésicos tópicos (bats) para liberação controlada de princípios ativos e bioadesivos anestésicos tópicos
GB201421013D0 (en) 2014-11-26 2015-01-07 Turzi Antoine New standardizations & medical devices for the preparation of platelet rich plasma (PRP) or bone marrow centrate (BMC)
EA201791225A1 (ru) 2014-12-03 2017-12-29 Велисепт Терапьютикс, Инк. Композиции и способы применения солабегрона с модифицированным высвобождением при симптомах нижних мочевых путей
CN107427548A (zh) 2014-12-08 2017-12-01 Jjsk 研发私人有限公司 载体分子组合物及相关方法
JP6936145B2 (ja) 2014-12-26 2021-09-15 コンジュゴン，インコーポレーテッド 創傷治療用及び表面治療用の細菌製剤の増殖、保存、及び使用のための方法及び組成物
US11040022B2 (en) 2015-02-05 2021-06-22 William H. Cross, III Compositions and methods for pain relief
US10947237B2 (en) 2015-03-11 2021-03-16 BioVersys AG Antimicrobial compounds and methods of making and using the same
CA2979529A1 (en) 2015-03-13 2016-09-22 Evolve Biosystems, Inc. Compositions that metabolize or sequester free sugar monomers and uses thereof
IL294055A (en) 2015-03-20 2022-08-01 Childrens Nat Medical Ct Generating virus or other antigen-specific t cells from a naive t cell population
JP7094533B2 (ja) 2015-04-10 2022-07-04 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫細胞捕捉デバイスおよびその製造および使用方法
RU2017134547A (ru) 2015-04-23 2019-04-09 Калейдо Байосайенсиз, Инк. Регуляторы микробиома и соответствующие варианты их применения
WO2016191545A1 (en) 2015-05-26 2016-12-01 Advaxis, Inc. Personalized delivery vector-based immunotherapy and uses thereof
EP3334439B1 (en) 2015-08-11 2021-10-13 Akeso Biomedical, Inc. Antimicrobial preparation and uses thereof
EP3337490A4 (en) 2015-08-20 2019-07-24 Genomatica, Inc. COMPOSITIONS AND MULTIPLEX SYSTEMS FOR COUPLED CELL-FREE TRANSCRIPTION TRANSLATION AND PROTEIN SYNTHESIS AND METHOD FOR USE THEREOF
WO2017051254A1 (en) 2015-09-25 2017-03-30 Legochem Biosciences, Inc. Compositions and methods related to anti-egfr antibody drug conjugates
EP3359085A4 (en) 2015-10-12 2019-09-18 Toth, Landy CONTROLLED AND PRECISE TREATMENT OF HEARTWOVEN
KR20180078329A (ko) 2015-11-25 2018-07-09 주식회사 레고켐 바이오사이언스 분지된 링커를 포함하는 항체-약물 접합체 및 이의 제조방법
HUE067016T2 (hu) 2015-11-25 2024-09-28 Ligachem Biosciences Inc Önfeláldozó csoportokat tartalmazó konjugátumok és ezekkel kapcsolos eljárások
EP3380125A4 (en) 2015-11-25 2019-08-28 LegoChem Biosciences, Inc. CONJUGATES WITH PEPTIDE GROUPS AND RELATED METHODS
CN105363018B (zh) 2015-12-02 2019-08-30 南京碧迪可医药科技有限公司 一种硫肽环素的新用途
EP3380899B1 (en) 2016-01-11 2020-11-04 Siemens Aktiengesellschaft Program randomization for cyber-attack resilient control in programmable logic controllers
WO2017127684A1 (en) 2016-01-21 2017-07-27 SeLux Diagnostics, Inc. Methods for rapid antimicrobial susceptibility testing
US20170209553A1 (en) 2016-01-22 2017-07-27 Transderm, Inc. Delivery of botulinum with microneedle arrays
JP7007298B2 (ja) 2016-01-25 2022-02-10 バイオ―ラッド ヨーロッパ ゲーエムベーハー デジタル微生物学
US11771752B2 (en) 2016-03-09 2023-10-03 Prime Bio, Inc. Composition for oral or nasal delivery of tetanus, diphtheria, and pertussis vaccine alone or in combination using neurotoxin associated proteins
CA3221941A1 (en) 2016-03-16 2017-09-21 Spogen Biotech Inc. Methods for promoting plant health using free enzymes and microorganisms that overexpress enzymes
CA3016922A1 (en) 2016-03-16 2017-09-21 Spogen Biotech Inc. Fusion proteins, recombinant bacteria, and exosporium fragments for animal health and aquaculture
MX2018012486A (es) 2016-04-12 2019-06-06 Illustris Pharmaceuticals Inc Composiciones para aplicacion topica de compuestos.
WO2017179775A1 (en) 2016-04-12 2017-10-19 Hugel Inc. Microstructure formulation techniques for botulinum toxin
CN109152803B (zh) 2016-04-25 2022-09-23 普梭梅根公司 用于表征与皮肤相关的病症的方法和系统
KR102399451B1 (ko) 2016-05-27 2022-05-23 입센 바이오팜 리미티드 트립토판 또는 타이로신으로 안정화된 액체 신경독 제형
US20170348263A1 (en) 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
TWI737742B (zh) 2016-06-22 2021-09-01 德商梅茲製藥有限兩合公司 肉毒桿菌毒素的預填充式注射器系統、具有其之套組以及其之使用
RU2760290C1 (ru) 2016-07-08 2021-11-23 Метаболик Эксплорер Способ ферментативной продукции целевых молекул микроорганизмами, включающими гены, кодирующие фосфотрансферазную систему (фтс) сахаров
WO2018038585A1 (ko) 2016-08-26 2018-03-01 주식회사 에이비바이오 보툴리눔 독소 및 안정화제를 포함하는 액상 제형 및 이의 제조방법
WO2018038301A1 (en) 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
WO2018039318A1 (en) 2016-08-26 2018-03-01 Akina, Inc. Biodegradable polymer formulations for extended efficacy of botulinum toxin
US11554108B2 (en) 2016-08-29 2023-01-17 Xeropedix, Inc. Methods and compositions for treating cutaneous fungal infections
AU2017326253B2 (en) 2016-09-13 2021-10-21 Allergan, Inc. Stabilized non-protein clostridial toxin compositions
KR102463881B1 (ko) 2016-10-04 2022-11-07 (주)메디톡스 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법
EP3532110B1 (en) 2016-10-26 2023-06-07 Oxy Solutions AS Formulations for oxygen delivery to body tissues
WO2018083692A1 (en) 2016-11-01 2018-05-11 Tamar Levin Novel methods for modulating protein expression in microorganisms
EP3888691A1 (en) 2016-11-14 2021-10-06 Hangzhou Dac Biotech Co., Ltd. Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
US20180147357A1 (en) 2016-11-29 2018-05-31 Amir Marashi Delivery method for preparation and administration of pharmaceutical compositions
US11040090B2 (en) 2016-12-08 2021-06-22 Prime Bio, Inc Botulinum neurotoxin compositions
EP3558281A4 (en) 2016-12-15 2020-07-08 Sharon Anavi-Goffer TREATMENT OF MENTAL DISORDERS, MOVEMENT AND BEHAVIOR
WO2018112419A1 (en) 2016-12-15 2018-06-21 uBiome, Inc. Method and system for characterizing diet-related conditions
WO2018125891A1 (en) 2016-12-27 2018-07-05 IMB Inc. Processing human milk for generating compositions of fortified human milk products
CN108322936B (zh) 2017-01-16 2023-06-02 中兴通讯股份有限公司 数据重传的方法及装置
US20190345436A1 (en) 2017-01-17 2019-11-14 White Dog Labs, Inc. Proteinic biomass preparation comprising a non-native organism of the clostridia class
WO2018136617A2 (en) 2017-01-18 2018-07-26 Evelo Biosciences, Inc. Methods of treating cancer
KR101744900B1 (ko) 2017-01-20 2017-06-08 주식회사 대웅 보툴리눔 독소를 포함하는 안정한 액상 조성물
KR101776659B1 (ko) 2017-02-27 2017-09-11 주식회사 쿼드메디슨 마이크로 니들 및 이의 제조방법
US11642319B2 (en) 2017-03-24 2023-05-09 The Regents Of The University Of Colorado Targeted nanogels for urinary bladder therapies
JP2020516318A (ja) 2017-04-17 2020-06-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 操作された共生細菌及び使用方法
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
WO2018206772A1 (de) 2017-05-11 2018-11-15 Immundiagnostik Ag Verfahren und testbesteck zur quantitativen bestimmung von biomarkern in fäkalproben
EP3632450A4 (en) 2017-05-24 2021-03-17 ATGC Co., Ltd. PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF A DISEASE CAUSING FOOT PAIN CONSISTING OF BOTULIC TOXIN AND HYALURONIC ACID AND METHOD OF TREATMENT OF FOOT PAIN USING THE SAME
MX2019014349A (es) 2017-05-31 2020-07-28 Allergan Inc Neurotoxina botulinica para el tratamiento de trastornos asociados con hiperactividad de los melanocitos y/o exceso de melanina.
FR3067928B1 (fr) 2017-06-23 2020-02-28 Fondation Mediterranee Infection Procede de conservation d'un echantillon de bacteries
US20210145955A1 (en) 2017-06-26 2021-05-20 Bonti, Inc. Clostridial neurotoxin formulations and use
BR112019028301A2 (pt) 2017-07-05 2020-07-14 Evelo Biosciences, Inc. composições e métodos para tratar câncer com o uso de bifidobacterium animalis ssp. lactis
KR20200054203A (ko) 2017-08-14 2020-05-19 소마젠 인크 질병-관련 마이크로바이옴 특성화 프로세스
WO2019046311A1 (en) 2017-08-28 2019-03-07 Revance Therapeutics, Inc. TRANSMUCOSAL COMPOSITIONS OF BOTULINUM TOXIN, KITS AND METHODS FOR TREATING BLADDER DISORDERS
TW201919671A (zh) 2017-08-30 2019-06-01 美商微辰生命有限公司 用於治療尿布疹、香港腳、接觸性皮膚炎、出汗及體臭之氨氧化微生物
WO2019051204A1 (en) 2017-09-08 2019-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services SYNERGISTIC COMBINATION OF IL4, INTERFERON GAMMA AND INTERFERON ALPHA RECEPTOR AGENTS FOR USE IN THE TREATMENT OF OVARIAN CANCER
AU2018330322A1 (en) 2017-09-08 2020-03-19 Evelo Biosciences, Inc. Bacterial extracellular vesicles
CN111526881A (zh) 2017-09-08 2020-08-11 伊夫罗生物科学公司 来自普雷沃菌的胞外囊泡
JP2020536052A (ja) 2017-10-03 2020-12-10 クリティテック・インコーポレイテッド 癌の治療のための免疫療法剤の全身送達と組み合わせた抗腫瘍粒子の局所送達
US10525111B2 (en) 2017-10-12 2020-01-07 Hugel, Inc. Microstructure formulation techniques for botulinum toxin
WO2019075452A1 (en) 2017-10-13 2019-04-18 Evelo Biosciences, Inc. IDENTIFICATION OF BACTERIA FOR CANCER THERAPY
JP2021502422A (ja) 2017-11-13 2021-01-28 エクストレモチェム・エルディーエー．Ｅｘｔｒｅｍｏｃｈｅｍ，Ｌｄａ． 生体分子の安定剤としての中性のグリコシル化されたアミド及びジアニオン性のグルクロン酸化された酸
US10493113B2 (en) 2017-11-14 2019-12-03 Evelo Biosciences, Inc. Compositions and methods for treating disease using a Blautia strain
US20210369599A1 (en) 2017-11-22 2021-12-02 Aobiome Llc Topical use and delivery of ammonia oxidizing microorganisms
EP3716768A4 (en) 2017-11-22 2021-08-25 Aobiome LLC TOPICAL USE AND ADMINISTRATION OF MICROORGANISMS OXIDIZING AMMONIA
WO2019118393A1 (en) 2017-12-11 2019-06-20 Board Of Regents, The University Of Texas System Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration
CN108205008B (zh) 2017-12-28 2020-04-21 深圳大学 一种基于有机光电化学晶体管的毒素传感器及其制备方法
KR20200108308A (ko) 2018-01-07 2020-09-17 아브라함 아미르 피부 증강을 위한 고부하 마이크로니들 및 조성물
MX2020007706A (es) 2018-01-24 2020-09-14 Omnigen Res Llc Combinacion de bacillus para administracion a animales.
EP3746121A1 (en) 2018-01-31 2020-12-09 Evelo Biosciences, Inc. Compositions and methods for treating immune disorders using lachnospiraceae bacteria
EP3749340A1 (en) 2018-02-06 2020-12-16 Evelo Biosciences, Inc. Compositions and methods for treating cancer and immune disorders using veillonella bacteria
EP3743079A1 (en) 2018-02-06 2020-12-02 Regen Lab SA Cross-linked hyaluronic acids and combinations with prp/bmc
KR102063475B1 (ko) 2018-02-22 2020-01-09 주식회사 에이비바이오 보툴리눔 독소, 안정화제, 및 국소마취제를 포함하는 액상 제형 및 이의 제조방법
EP3758513A1 (en) 2018-02-28 2021-01-06 c-LEcta GmbH Enzymatic in-situ fortification of food with functional carbohydrates
WO2019178055A1 (en) 2018-03-12 2019-09-19 Evelo Biosciences, Inc. Extracellular vesicles from burkholderia
WO2019178359A1 (en) 2018-03-15 2019-09-19 Adepthera Llc Gel-forming polypeptides
WO2019174560A1 (zh) 2018-03-14 2019-09-19 必康生技（香港）有限公司 用于生物流体净化的组合物
WO2019178494A1 (en) 2018-03-15 2019-09-19 Evelo Biosciences, Inc. Compositions and methods for treating cancer and inflammation using tyzzerella nexilis
WO2019178487A2 (en) 2018-03-15 2019-09-19 Evelo Biosciences, Inc. Compositions and methods for treating disease using klebsiella quasipneumoniae subsp. similipneumoniae
WO2019178490A1 (en) 2018-03-15 2019-09-19 Evelo Biosciences, Inc. Compositions and methods for treating cancer and inflammation using klebsiella oxytoca
US20190321427A1 (en) 2018-04-18 2019-10-24 G&S Laboratories, Inc. Compositions to Treat Anal Fissures
WO2019211382A1 (en) 2018-05-03 2019-11-07 Crigasseni Ag Probiotic bacterial strains producing antimicrobial proteins and compositions comprising these for use in the treatment of diarrheal and other microbial diseases
WO2019226599A1 (en) 2018-05-22 2019-11-28 Alkalidx, Inc. Diagnostics and treatments of anesthetic insensitive subjects
US11464858B2 (en) 2018-06-23 2022-10-11 University Of Wyoming Magnetic nanoparticle delivery system for pain therapy
KR20210057129A (ko) 2018-09-13 2021-05-20 알레간 인코포레이티드 클로스트리디움 독소-히알루론산 조성물

Also Published As

Publication number Publication date
WO2018053021A1 (en) 2018-03-22
ES2755816T3 (es) 2020-04-23
EP3432916B1 (en) 2019-08-14
CO2019003630A2 (es) 2019-06-28
BR112019004929A2 (pt) 2019-06-04
KR20240023684A (ko) 2024-02-22
JP2019526611A (ja) 2019-09-19
CY1122276T1 (el) 2020-11-25
IL265109B2 (en) 2024-05-01
JP7217700B2 (ja) 2023-02-03
US20230355723A1 (en) 2023-11-09
WO2018053004A3 (en) 2018-04-26
CN109803672A (zh) 2019-05-24
RU2019110875A3 (es) 2021-01-12
SI3432916T1 (sl) 2020-01-31
MX2023004911A (es) 2023-05-16
TWI773686B (zh) 2022-08-11
KR20190053884A (ko) 2019-05-20
US20210369821A1 (en) 2021-12-02
EP3639848A3 (en) 2020-12-16
CA3036095A1 (en) 2018-03-22
CY1122263T1 (el) 2020-11-25
JP2019526609A (ja) 2019-09-19
DK3436054T4 (da) 2022-08-29
EP3432916A1 (en) 2019-01-30
JP7675053B2 (ja) 2025-05-12
PL3436054T5 (pl) 2023-01-30
RU2762607C2 (ru) 2021-12-21
US10973890B2 (en) 2021-04-13
US20230173041A1 (en) 2023-06-08
CA3035473A1 (en) 2018-03-22
KR20220132013A (ko) 2022-09-29
DK3432916T3 (da) 2019-11-11
PT3432916T (pt) 2019-11-20
CN109803673A (zh) 2019-05-24
IL265109A (es) 2019-04-30
AU2021282546B2 (en) 2025-03-20
PL3432916T3 (pl) 2020-04-30
KR20190053214A (ko) 2019-05-17
SA519401298B1 (ar) 2021-12-21
US20240299509A1 (en) 2024-09-12
RU2019110912A3 (es) 2020-11-30
EP3639848A2 (en) 2020-04-22
RU2019110875A (ru) 2020-10-15
KR20250038828A (ko) 2025-03-19
AU2017326253B2 (en) 2021-10-21
ES2755816T5 (es) 2022-10-24
BR112019004935A2 (pt) 2019-06-04
KR102635959B1 (ko) 2024-02-14
US20190247476A1 (en) 2019-08-15
RU2019110912A (ru) 2020-10-15
SMT201900625T1 (it) 2020-01-14
AU2025204621A1 (en) 2025-07-10
KR102558892B1 (ko) 2023-07-21
RS59600B1 (sr) 2020-01-31
US20240252604A1 (en) 2024-08-01
KR102444230B1 (ko) 2022-09-19
US20210290739A1 (en) 2021-09-23
PT3436054T (pt) 2019-11-19
PH12019500501A1 (en) 2019-05-27
TW201822786A (zh) 2018-07-01
SI3436054T1 (sl) 2020-01-31
AU2021282546A1 (en) 2022-01-06
IL308091A (en) 2023-12-01
ES2755815T3 (es) 2020-04-23
US10369190B2 (en) 2019-08-06
US12171816B2 (en) 2024-12-24
KR20230004945A (ko) 2023-01-06
CN117959415A (zh) 2024-05-03
HUE046449T2 (hu) 2020-03-30
AU2017327369A1 (en) 2019-05-02
JP2022179500A (ja) 2022-12-02
US20180071361A1 (en) 2018-03-15
AU2017326253A1 (en) 2019-04-11
EP3436054A2 (en) 2019-02-06
EP3436054B2 (en) 2022-07-27
HRP20191966T1 (hr) 2020-01-24
RS59600B2 (sr) 2022-10-31
US20230355724A1 (en) 2023-11-09
US12144847B2 (en) 2024-11-19
TW202247855A (zh) 2022-12-16
US20190351034A1 (en) 2019-11-21
MX2019002835A (es) 2019-09-04
DK3436054T3 (da) 2019-11-11
EP3626259A1 (en) 2020-03-25
IL265109B1 (en) 2024-01-01
HUE046290T2 (hu) 2020-02-28
PL3436054T3 (pl) 2020-06-15
LT3436054T (lt) 2019-11-25
HRP20191966T4 (hr) 2022-09-16
SI3436054T2 (sl) 2022-09-30
EP3436054B1 (en) 2019-08-14
KR102480965B1 (ko) 2022-12-26
WO2018053004A2 (en) 2018-03-22

Similar Documents

Publication Publication Date Title
CL2019000586A1 (es) Composiciones de toxinas clostridiales no proteicas.
BR112018015824A2 (pt) composições para higiene pessoal
BR112017022584A2 (pt) regime para tratamento dos cabelos com o uso de um condicionador concentrado de espuma em aerossol
BR112015032736A2 (pt) inibidores de bromodomínio cristalino
CL2017001115A1 (es) Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf.
UY34617A (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas
BR112015023391A2 (pt) formulações compreendendo conjugado droga-anticorpo anti-egfr
CL2020002252A1 (es) Formulación oftálmica.
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
CL2017001964A1 (es) Encapsulado de agentes activos de alta potencia.
CO2019011265A2 (es) Moduladores de la expresión de pcsk9
UY36898A (es) Variantes de hppd y métodos de uso
MX394795B (es) Moleculas que tienen cierta utilidad pesticida, intermedios, composiciones y procesos relacionados con las mismas.
BR112021004771A2 (pt) Composições de ácido hialurônico-toxina clostridial
AR103174A1 (es) Composiciones adyuvantes acuosas que contienen electrolito, composiciones que contienen ingrediente activo y su uso
MX2017009827A (es) Formulacion farmaceutica.
MX2016012248A (es) Composiciones para el tratamiento de autodigestion.
CL2021001246A1 (es) Moduladores de expresión irf5.
BR112017001888A2 (pt) formulações biológicas para instilação intravesical
BR112017018618A2 (pt) odorizante de osmanthus
EA201892376A1 (ru) Комбинированный состав трех противовирусных соединений
BR112018073649A2 (pt) agente de controle de espuma de poliéter, formulação agroquímica, e, processo para preparar uma formulação agroquímica.
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino
BR112016023737A2 (pt) ?composição agrícola, e, método de condicionamento de água?
MX387370B (es) Composición líquida que contiene pradofloxacina.